Related Experiment Video
Updated: Jul 19, 2026

Modifying Levels of Maternal Dietary Folic Acid or Choline to Study the Impact of Deficiencies on Offspring Health Outcomes
Published on: June 28, 2024
Can folic acid protect against congenital heart defects in Down syndrome?
Willemijn M Meijer1, Martha M Werler, Carol Louik
1Slone Epidemiology Center, Boston University, Boston, Massachusetts 02215-1201, USA.
Insights
Folic acid (FA) supplementation did not show a protective effect against heart anomalies in infants with Down syndrome (DS). This study found no evidence that maternal FA use prevents congenital heart defects in children with DS.
Area of Science:
- Medical research
- Genetics
- Public health
Background:
- Congenital heart anomalies are common in infants with Down syndrome (DS).
- Maternal factors may influence the risk of heart anomalies in DS infants.
- Previous studies suggested folic acid (FA) may protect against congenital heart defects.
Purpose of the Study:
- To investigate if first-trimester folic acid (FA) use protects against heart anomalies in children with Down syndrome (DS).
Main Methods:
- Case-control study of women with liveborn DS children (1976-1997).
- Cases: DS infants with heart anomalies; Controls: DS infants without heart anomalies.
- Exposure defined as FA use for ≥4 days/week during the first trimester of pregnancy.
Main Results:
- No protective effect of FA was found for heart anomalies overall in DS infants (OR 0.95).
- FA showed no protective effect for specific defects like conotruncal defects, VSDs, ASDs, or ECDs.
- 49% of cases and 46% of controls were exposed to FA.
Conclusions:
- This study found no evidence that folic acid (FA) protects against heart anomalies in infants with Down syndrome (DS).
Background:
Several studies have suggested a protective effect of folic acid (FA) on congenital heart anomalies. Down syndrome (DS) infants are known to have a high frequency of heart anomalies. Not all children with DS suffer from heart anomalies, which raises the question whether maternal factors might affect the risk of these anomalies. Our objectives were to investigate whether first-trimester FA use protects against heart anomalies among DS children.
Methods:
Women with liveborn DS children participating in the Slone Epidemiology Center Birth Defects Study between 1976 and 1997 were included. We performed case-control analyses using DS, with heart anomalies as cases and DS, without heart anomalies as controls. Subanalyses were performed for defects that have been associated with FA in non-DS populations (conotruncal, ventricular septal [VSD]) and for those that are associated with DS (ostium secundum type atrial septal defects [ASD] and endocardial cushion defects [ECD]). Exposure was defined as the use of any FA-containing product for an average of at least 4 days per week during the first 12 weeks of pregnancy, whereas no exposure was defined as no use of FA in these 12 weeks.
Results:
Of the 223 cases, 110 (49%) were exposed versus 84 (46%) of the 184 controls. After adjustment for possible confounders, no protective effect of FA was found on heart anomalies overall (OR 0.95, 95% CI: 0.61-1.47) nor separately for conotruncal defects, VSDs, ASDs, or ECDs.
Conclusions:
Our study does not show a protective effect of FA on heart anomalies among infants with DS.
Related Concept Videos
Meiosis vs. Mitosis
Before the start of mitosis and meiosis I, the cell synthesizes DNA, resulting in two homologous copies of each chromosome. DNA synthesis is...
Teratogenicity
Meiosis I
Fetal Circulation
Two umbilical arteries transport blood from the fetus to the placenta. At the placenta, the blood absorbs oxygen and nutrients while simultaneously eliminating waste products. This oxygen-enriched and nutrient-rich blood then returns to the fetus through one...
Vitamins
Nondisjunction

